Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to explore and compare the efficacy of Cetuximab (ERBITUX®)
added to two concurrent chemoradiotherapy platforms of different intensity in locally
advanced head and neck cancer.